https://www.thebodypro.com/category/dolutegravir-tivicay/tag/croi-conference-on-retroviruses-and-opportunistic-infections
Dolutegravir (Tivicay)

CROI (Conference on Retroviruses and Opportunistic Infections)

The Latest

Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows Img

Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows

Unlike some previous studies that focused on early pregnancy, this study showed no associated congenital disabilities with either drug.

Twice-Daily Dolutegravir Is Effective and Tolerable With Rifampicin Img

Twice-Daily Dolutegravir Is Effective and Tolerable With Rifampicin

24-week interim results from the INSPIRING study presented at CROI 2018 show that dolutegravir 50 mg twice daily is effective and well-tolerated in adults with HIV/TB receiving rifampicin-based TB treatment.

Significant Interaction Between Once-Weekly Isoniazid/Rifapentine and Daily Dolutegravir: Study Stopped Due to Toxicity Img

Significant Interaction Between Once-Weekly Isoniazid/Rifapentine and Daily Dolutegravir: Study Stopped Due to Toxicity

Serious toxicities were seen in participants in a drug-drug interaction study of once-weekly isoniazid and rifapentine with once-daily dolutegravir, leading to its early termination.

Promo Image

Long-Acting HIV Treatment: 5 Myths and Realities

Long-acting antiretrovirals: Are they the future of HIV treatment or will the future pass them by? Researcher Charles W. Flexner recently addressed several common myths.

Two-Drug HIV Treatment Regimens Effective in Latest Studies Img

Two-Drug HIV Treatment Regimens Effective in Latest Studies

"This is really the first step in demonstrating that two-drug regimens can be as effective as three-drug regimens," says Kimberly Smith, M.D., M.P.H.

Dolutegravir Monotherapy Studies Halted Due to Integrase Resistance: Dual Therapy Studies Continue Img

Dolutegravir Monotherapy Studies Halted Due to Integrase Resistance: Dual Therapy Studies Continue

Several studies at CROI 2017 reported a similar conclusion: reducing ART to dolutegravir monotherapy should be stopped.

Dolutegravir Exposure Increases When Fixed-Dose Combination Tablets Are Crushed Img

Dolutegravir Exposure Increases When Fixed-Dose Combination Tablets Are Crushed

Dolutegravir exposure was higher after crushing the originator fixed-dose combination tablet and after crushing was followed by enteral nutrition, compared to the whole tablet.

Dolutegravir Pharmacokinetics, Safety and Efficacy in Young Children Img

Dolutegravir Pharmacokinetics, Safety and Efficacy in Young Children

Dolutegravir granules-in-suspension achieved satisfactory exposures in children aged between 2 and 6 years, according to data presented at CROI2017.

Dolutegravir: 48-Week Results in Children Age 6 to 12 Years Old Img

Dolutegravir: 48-Week Results in Children Age 6 to 12 Years Old

Dolutegravir is safe and effective in children age 6-12 years, according to results presented at CROI 2016.